Plaintiff states alleged that the makers of Suboxone, a drug used to treat opioid addiction, engaged in a scheme to block generic competitors and raise prices. Specifically, they are conspiring to switch Suboxone from a tablet version to a film in order to prevent or delay generic entry. The states allege that the manufacturers engaged in “product hopping” in which a company makes slight changes to its product to extend patent protections and prevent generic alternatives. The complaint was filed under seal. The plaintiff states settled with Indivior in June 2023. The settlement requires Indivior to pay the states $102.5 million. Indivior is also required to inform the states of all Citizen Petitions it submits to the U.S. Food and Drug Administration (FDA) and provide notice about new products and/or a change in corporate control to help ensure that Indivior doesn’t repeat their monopolistic actions.